TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04842682

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Combi 1 group
Description: CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 1.0 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid; and combined with DNA at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combi 3 group
Description: CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 3.0 and 1.0 mg/injection, i.e. 1.2 ml subcutaneous route in right deltoid; and combined with DNA at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1.2 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24.
Study: NCT06239311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Solution for injection in prefilled pen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection in prefilled pen
Study: NCT05446597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Symptom-specific Headache Treatment
Description: Greater Occipital Nerve Block

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom-specific Dizziness &/or Neck Pain Treatment
Description: Cervicovestibular Physiotherapy Treatment
Study: NCT06106490

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the effect of adding pulsed radiofrequency (PRF) modality to suprascapular nerve injection with ultrasound glenohumeral steroid in chronic shoulder pain patients
Description: Suprascapular nerve block group: Patients will receive ultrasound guided intra articular Gleno-humeral steroid injection of Diprofos® (betamethasone 14 mg/ 2ml) and ultrasound guided suprascapular nerve block US SSN with 10mL of 0.25% preservative-free bupivacaine~Pulsed radiofrequency group: Patients will receive ultrasound guided intra articular Gleno-humeral steroid injection of Diprofos® (betamethasone 14 mg/ 2ml) and ultrasound guided suprascapular nerve block US SSN with 10mL of 0.25% preservative-free bupivacaine with application of pulse PRF at 42 Celsius of suprascapular nerve for 480 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the effect of adding pulsed radiofrequency (PRF) modality to suprascapular nerve injection with ultrasound glenohumeral steroid in chronic shoulder pain patients
Description: Suprascapular nerve block group: Patients will receive ultrasound guided intra articular Gleno-humeral steroid injection of Diprofos® (betamethasone 14 mg/ 2ml) and ultrasound guided suprascapular nerve block US SSN with 10mL of 0.25% preservative-free bupivacaine~Pulsed radiofrequency group: Patients will receive ultrasound guided intra articular Gleno-humeral steroid injection of Diprofos® (betamethasone 14 mg/ 2ml) and ultrasound guided suprascapular nerve block US SSN with 10mL of 0.25% preservative-free bupivacaine with application of pulse PRF at 42 Celsius of suprascapular nerve for 480 seconds.
Study: NCT06376331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: washed microbiota transplantation
Description: The prepared microbiota suspension was infused into the participates' lower gut.
Study: NCT06563336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMG-driven hand robot training
Description: Robot rehabilitation program was applied with Hand of Hope®(Rehab-Robotics Company, Hong Kong), and EMG-driven exoskeleton. The biggest advantage of this system is that it measures the residual muscle activity values with surface EMG(sEMG) sensors. The residual muscles activity is used by giving feedback to the patient.~This treatment program, which was applied to both groups in the study, consisted of joint range of motion (ROM) exercises, stretching exercises for burn scars, strengthening exercises using putty or bands, and fine motor training such as writing and using a chopstick.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional occupational training
Description: This treatment program, which was applied to both groups in the study, consisted of joint range of motion (ROM) exercises, stretching exercises for burn scars, strengthening exercises using putty or bands, and fine motor training such as writing and using a chopstick.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional occupational training
Description: This treatment program, which was applied to both groups in the study, consisted of joint range of motion (ROM) exercises, stretching exercises for burn scars, strengthening exercises using putty or bands, and fine motor training such as writing and using a chopstick.
Study: NCT06562452

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Injectable platelet rich fbirin
Description: fter the leveling and alignment phase, the canines were retracted with 150gm forces. The i-PRF was prepared from the blood of each patient then injected immediately before canine retraction on the buccal and palatal aspects of the extraction sites. Digital model were obtained at five time points: before tooth extraction (T0) and in the fourth week (T1), eighth week (T2), twelfth week (T3), sixteenth week (T4) from the beginning of distalization.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Injectable platelet rich fbirin
Description: fter the leveling and alignment phase, the canines were retracted with 150gm forces. The i-PRF was prepared from the blood of each patient then injected immediately before canine retraction on the buccal and palatal aspects of the extraction sites. Digital model were obtained at five time points: before tooth extraction (T0) and in the fourth week (T1), eighth week (T2), twelfth week (T3), sixteenth week (T4) from the beginning of distalization.
Study: NCT04872075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concert
Description: People attending a concert in a closed area, with a mask

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rapid nasopharyngeal antigen test for Sars-Cov-2
Description: A nasopharyngeal swab at inclusion (up to 3 days before concert) to confirm eligibility

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid nasopharyngeal antigen test for Sars-Cov-2
Description: A nasopharyngeal swab at inclusion (up to 3 days before concert) to confirm eligibility

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Saliva Sample
Description: Saliva samples sent by participant at Day0 and Day7

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva Sample
Description: Saliva samples sent by participant at Day0 and Day7
Study: NCT06045546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 5-5-5-8 technique
Description: the new technique of 5-5-5-8 for laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 10-10-10-5 technique
Description: the standard technique of 10-10-10-5 for laparoscopic cholecystectomy
Study: NCT04821349

Intervention type: DEVICE
Group type: OTHER
Intervention: Capsule endoscopy
Description: A consecutive series of patients recruited by 12 European centers based on the indication of OGIB will undergo capsule endoscopy examination.~Capsule endoscopy will be performed in each site according to local rules and requirements, and the study protocol will concern only the post-procedure analysis on reading modalities for each patient.
Study: NCT06495684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS + Social Learning
Description: Anodal tDCS lowers neuronal membrane potentials, leading to increased probability of depolarization from incoming stimuli.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Placebo Anodal tDCS + Social Learning
Description: Social learning tasks are completed on a computer and consist of viewing video modeling of social interactions, facial emotion detection practice, and videos for emotion and empathy learning.
Study: NCT05315999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron Hydrochloride
Description: Palonosetron (500µg): single dose per os 1-2 hours before the start of opioid-therapy (WHO II \& III)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: single dose per os 1-2 hours before the start of opioid-therapy (WHO II \& III)
Study: NCT05384769

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liquid Biopsy
Description: Undergo liquid biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liquid Biopsy
Description: Undergo liquid biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Dose Computed Tomography of the Chest
Description: Undergo low dose CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Dose Computed Tomography of the Chest
Description: Undergo low dose CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05640765

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care services

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care services

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive additional educational and supportive material

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Participate in BeWell360-CG Care Model sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05446597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal Concussion Treatment
Description: Lite combination of headache advice, general physiotherapy exercises, mindfulness, visualization, and relaxation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal Concussion Treatment
Description: Lite combination of headache advice, general physiotherapy exercises, mindfulness, visualization, and relaxation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal Concussion Treatment
Description: Lite combination of headache advice, general physiotherapy exercises, mindfulness, visualization, and relaxation
Study: NCT05959499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR6002A
Description: One tablet administered alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR6002B
Description: One tablet administered alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR6002
Description: One capsule administered alone
Study: NCT04718064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo once daily, for three consecutive days,
Study: NCT06069063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zafirlukast
Description: Oral zafirlukast is approved to treat asthma and been shown in previous trials to be effective in blocking or mitigating the symptoms of people allergic to cat dander

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zafirlukast
Description: Oral zafirlukast is approved to treat asthma and been shown in previous trials to be effective in blocking or mitigating the symptoms of people allergic to cat dander
Study: NCT05434910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changes in mean arterial pressure
Description: MAP set at 65 mmHg for 25 min by infusion of noradrenaline. MAP set at 80 mmHg for 25 min by infusion of noradrenaline. MAP set at 95 mmHg for 25 min by infusion of noradrenaline.
Study: NCT06205134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: Epinephrine injection
Description: Autoinjector for intramuscular, single-use, 0.3mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: Epinephrine injection
Description: Autoinjector for intramuscular, single-use, 0.3mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: FMXIN002 3.6mg
Description: Nasus Pharma nasal powder spray 3.6 mg, single use in one nostril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: FMXIN002 3.6mg
Description: Nasus Pharma nasal powder spray 3.6 mg, single use in one nostril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: FMXIN002 4.0mg
Description: Nasus Pharma nasal powder spray 4.0 mg, single use in one nostril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: FMXIN002 4.0mg
Description: Nasus Pharma nasal powder spray 4.0 mg, single use in one nostril
Study: NCT05218629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib, PD-1 inhibitor
Description: Anlotinib, 8-12 mg/day, orally, day 1-14; PD-1 inhibitor 200 mg iv, every 21 days one cycle
Study: NCT05522361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: administered to participants per product label insert
Study: NCT06081569

Intervention type: DIAGNOSTIC_TEST
Intervention: gait video; speech video; facial expression video;
Description: The videos of participants' gait, facial expression, and speech will be recorded and analyzed further. Other routine diagnostic tests will also be performed such as imaging of MRI, cognitive scales, etc.

Intervention type: DIAGNOSTIC_TEST
Intervention: gait video; speech video; facial expression video;
Description: The videos of participants' gait, facial expression, and speech will be recorded and analyzed further. Other routine diagnostic tests will also be performed such as imaging of MRI, cognitive scales, etc.

Intervention type: DIAGNOSTIC_TEST
Intervention: gait video; speech video; facial expression video;
Description: The videos of participants' gait, facial expression, and speech will be recorded and analyzed further. Other routine diagnostic tests will also be performed such as imaging of MRI, cognitive scales, etc.
Study: NCT05355545

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtually supervised exercise
Description: Participants will participate twice weekly in an live exercise program that they will access through a computer connected to the Internet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtually supervised exercise
Description: Participants will participate twice weekly in an live exercise program that they will access through a computer connected to the Internet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Participants will first participate in a once weekly live health education class that they will access through a computer connected to the Internet. During the second half of the study, participants will participate twice weekly in an live exercise program that they will access through a computer connected to the Internet.
Study: NCT05911308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1,500 mg Durvalumab IV infusion will be given on day 1 of each cycle for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV infusion will be given on day 1 of each cycle for 3 cycles. The dose will be AUC 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abequolixron
Description: 100 or 120 mg Abequolixron will be administered by mouth twice a day for 5 days followed by 2 days off throughout your treatment (5 days a week for up to 9 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 100 mg/m2 Abraxane will be given by IV infusion on days 1, 8, and 15 of each cycle for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 pemetrexed will be given by IV infusion on day 1 of each cycle for 3 cycles.
Study: NCT05947591

Intervention type: BEHAVIORAL
Intervention: foot posture index
Description: the tendency to foot pronation in healthy subjects will be compared during one hour of walking versus one hour of running in subjects who usually run.

Intervention type: BEHAVIORAL
Intervention: foot posture index
Description: the tendency to foot pronation in healthy subjects will be compared during one hour of walking versus one hour of running in subjects who usually run.
Study: NCT06133933

Intervention type: DEVICE
Intervention: Pain Threshold using algometer/dolorimeter
Description: These patients who consent to participation in the study will receive a preoperative pain threshold measured using a pain algometer/dolorimeter. We will rely on the completion of the questionnaires, opioid consumption journal, and surveys to establish a correlation between pre-operative pain threshold and post-operative outcomes.
Study: NCT05929352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musical Intervention
Description: A trained musician-facilitator will convene a series of four weekly two-hour sessions to which groups of five participants will be invited. The facilitator provides keyboard, professional microphone, recording interface, headphones, guitar, computer and a Digital Audio Workstation (DAW) for recording.
Study: NCT04801589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: For patients in the dexmedetomidine group, dose will range from 0.2-2.0 mcg/kg/hr. For example, a 10 kg patient on an infusion of 1 mcg/kg/hr of dexmedetomidine would receive 10 mcg of study drug per hour. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the mini-MENDS study steering committee.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: For patients in the midazolam group, dose will range from 0.025-0.25 mg/kg/hr. For example, a 10 kg patient on an infusion of 0.15 mg/kg/hr of midazolam would receive 1.5 mg of midazolam per hour. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the mini-MENDS study steering committee.
Study: NCT06544200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymeric Hydrogel Matrix
Description: application of Polymeric Hydrogel Matrix along the suture line at the completion of lung resection
Study: NCT06560060

Intervention type: OTHER
Intervention: No intervention
Description: There are no interventions. The only medical procedure is a blood draw
Study: NCT05548504

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon
Description: 50-66Gy/ 24 fractions, inhomogeneous dose distribution photon therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton
Description: 50-66Gy/ 24 fractions, inhomogeneous dose distribution proton therapy
Study: NCT05087186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided imagery and FLASH technique
Description: Five virtual group sessions delivered by psychological therapists;~* Sessions 1 and 2: Guided imagery~* Sessions 3 and 4: FLASH technique~* Session 5: Refresher on guided imagery and FLASH technique
Study: NCT05401786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Anti-CTLA-4
Study: NCT06457932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback training
Description: An 8-week intervention based on daily 10-minute HRV biofeedback training at rest using the Pulse HRV smartphone application.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided meditation
Description: An 8-week intervention based on daily 10-minute guided meditation sessions led by an instructor with over 20 years of experience in teaching meditation.
Study: NCT05401786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: PD-1 inhibition

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiotherapy
Study: NCT04772547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin Only Product
Description: enteral medication administration, serial blood draws, and outcome assessment
Study: NCT05962372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally tailored food and diet advice
Description: Puerto Rico-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard healthy eating advice
Description: Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips included in the My Plate For A Healthy Puerto Rico dietary recommendations.
Study: NCT05619419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-enhanced positive affect induction
Description: Participants will receive brief psychoeducation about biopsychosocial pain management and practice with the MPAI via guided audio recording. They will then listen to the audio recording a final time before beginning the cold pressor test for experimental pain induction. They will be instructed to continue using the MPAI to manage pain during the cold pressor test.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing Meditation
Description: Participants will receive brief psychoeducation about biopsychosocial pain management and practice with the BM via guided audio recording. They will then listen to the audio recording a final time before beginning the cold pressor test for experimental pain induction. They will be instructed to continue using the BM to manage pain during the cold pressor test.
Study: NCT05838872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minuteful - Kidney Urine Analysis Test System
Description: Urine samples were collected and tested by a lay user, using the Minuteful - Kidney test device. The lay user test results were compared to the results obtained by testing the same urine sample on the comparison device, the URiSCAN Optima.